An introduction to pharmacovigilance by patrick waller

All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. Foreword No drug which is pharmacologically effective is without hazard. The legislation underpinning the centralised system of authorisation i. In any case, we know that all pharmacologically active substances have the potential to cause harm. Ideally, a balance sheet would be constructed and the debits i.

Uploader: Yozilkree
Date Added: 14 May 2017
File Size: 58.11 Mb
Operating Systems: Windows NT/2000/XP/2003/2003/7/8/10 MacOS 10/X
Downloads: 11465
Price: Free* [*Free Regsitration Required]





Council for the Organisation of Medical Sciences. A number of points about these methods are worth emphasising.

An Introduction to Pharmacovigilance

The non-steroidal anti-inflammatory drug, tiaprofenic acid, had been known to cause cystitis for over a decade but a series of cases was then reported indicating that, if the reaction was not recognised and the drug was continued in the long term, severe chronic cystitis might occur.

Problems experienced by patients when they stop treatments are often quite difficult to assess because they could possibly be related to recurrence of the disease. With regard to drug safety, some examples of registries are as follows: Wij nemen binnen een werkdag contact met u op.

During this decade, pharmaceutical companies started to conduct their own post-marketing surveillance studies and UK guidelines related to their conduct were drawn up in Knowing, for example, that an adverse effect mostly occurs in people who are poor metabolisers of specific hepatic cytochrome substrates could be important in developing preventive measures.

When individual case causality assessment is to be performed, Walller would suggest using the following four categories into which a case might be placed: However, to do so requires that all potential confounders are identified and adequately measured.

At the time, the European Medicines Agency had recently been formed but co-operation on nationally authorised products was in its infancy. Possible signals have often been evaluated or dismissed on the basis of subjective judgements but two methods of prioritisation have been proposed: It therefore pharmacoviilance not detract from the primary purpose of wallre method but it does mean that interpretation of the data during subsequent monitoring is fraught with difficulty.

So thalidomide led directly to the initial development of the systems we now have, although it is only quite recently i. Conclusion This chapter has considered the main types of data which are used in pharmacovigilance and their strengths and limitations.

Chapter 5 will consider how companies and regulators should interact to ensure that the process awller appropriately applied. Reports are submitted on a voluntary basis and information from them is entered onto a database which is screened regularly for signals. Therefore there is a need to be sure that any observed association is not simply a consequence of that. Rarely can a drug safety issue be considered completely and permanently resolved.

It should also be noted that regulators have obligations towards industry, in particular the timely transmission of reports which they receive from health professionals to the MA holder.

Three cases are generally considered to be the minimum number of cases needed. Those embarking on a career in pharmacovigilance or simply wishing to gain a sound working knowledge of the discipline will find what they need to know here in one place. In the UK, only part of the country is covered by regional centres.

An Introduction to Pharmacovigilance - Patrick Waller - Häftad () | Bokus

The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose.

It was reintroduced with compulsory blood monitoring around This reaction occurs at therapeutic doses, usually after some months of treatment; females and older people are at the greatest risk. When OCs are stopped abruptly by sexually active women without immediate use of an effective alternative, unwanted pregnancies occur and abortion rates increase. One specific problem arising 50 Chapter 4 from proportionate methods is that large effects may swamp and therefore mask smaller ones.

Safety is a moving ball — there is a need to re-evaluate it as experience accumulates. Some content that appears in print may not be available in electronic books.

Proportionately fewer controls had used the drug and therefore the odds ratio in this study was more than two.

The key estimate from this study is the attributable risk of 0. VTE is a sufficiently rare outcome in ny women that it would be extremely difficult to conduct a large enough clinical trial to detect a doubling of risk.

Note how the PRR fluctuates over time — ADR databases are dynamic — and that the increase in the period — is an effect of publicity about the reaction.

Wiley also publishes its books in a variety of electronic formats. The final introdkction criteria are: The options available are suspension, revocation or variation.